Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | adenosine A2a receptor | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | follicle stimulating hormone receptor | adenosine A2a receptor | 412 aa | 336 aa | 22.3 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Echinococcus multilocularis | NADPH dependent diflavin oxidoreductase 1 | 0.0171 | 1 | 1 |
Schistosoma mansoni | cytochrome P450 reductase | 0.0171 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0085 | 0 | 0.5 |
Brugia malayi | FAD binding domain containing protein | 0.0171 | 1 | 1 |
Giardia lamblia | Hypothetical protein | 0.0152 | 0.7743 | 0.5 |
Trypanosoma brucei | NADPH-cytochrome p450 reductase, putative | 0.0171 | 1 | 0.5 |
Trypanosoma cruzi | p450 reductase, putative | 0.0171 | 1 | 0.5 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0171 | 1 | 0.5 |
Giardia lamblia | Nitric oxide synthase, inducible | 0.0152 | 0.7743 | 0.5 |
Schistosoma mansoni | 5-methyl tetrahydrofolate-homocysteine methyltransferase reductase | 0.0106 | 0.2407 | 0.2407 |
Trypanosoma brucei | NADPH-dependent diflavin oxidoreductase 1 | 0.0171 | 1 | 0.5 |
Echinococcus granulosus | NADPH cytochrome P450 reductase | 0.0171 | 1 | 1 |
Trichomonas vaginalis | sulfite reductase, putative | 0.0171 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0171 | 1 | 1 |
Trypanosoma brucei | NADPH--cytochrome P450 reductase, putative | 0.0171 | 1 | 0.5 |
Loa Loa (eye worm) | FAD binding domain-containing protein | 0.0171 | 1 | 1 |
Mycobacterium ulcerans | formate dehydrogenase H FdhF | 0.0171 | 1 | 0.5 |
Plasmodium falciparum | nitric oxide synthase, putative | 0.0171 | 1 | 0.5 |
Trypanosoma cruzi | NADPH-dependent FMN/FAD containing oxidoreductase, putative | 0.0171 | 1 | 0.5 |
Plasmodium vivax | NADPH-cytochrome p450 reductase, putative | 0.0171 | 1 | 1 |
Schistosoma mansoni | NADPH flavin oxidoreductase | 0.0086 | 0.0151 | 0.0151 |
Echinococcus granulosus | NADPH dependent diflavin oxidoreductase 1 | 0.0171 | 1 | 1 |
Toxoplasma gondii | flavodoxin domain-containing protein | 0.0085 | 0 | 0.5 |
Echinococcus multilocularis | NADPH cytochrome P450 reductase | 0.0171 | 1 | 1 |
Leishmania major | p450 reductase, putative | 0.0171 | 1 | 1 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0171 | 1 | 0.5 |
Trypanosoma cruzi | cytochrome P450 reductase, putative | 0.0171 | 1 | 0.5 |
Chlamydia trachomatis | sulfite reductase | 0.0106 | 0.2407 | 0.5 |
Leishmania major | NADPH-cytochrome p450 reductase-like protein | 0.0171 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Ki (binding) | = 0.7 nM | Displacement of [3H]SCH58261 from human adenosine A2A receptor expressed in HEK293 cells | ChEMBL. | 19109019 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.